WASHINGTON, D.C. — The U.S. Senate is scheduled to hold a full vote on the Clear Labels Act, legislation that has undergone amendments regarding drug manufacturing transparency. Senators removed the requirement for drug labels to include a unique facility identification number, known as a DUNS number, and extended the compliance timeline from one year to five years after passage.

The updated legislation requires drug labels to include factory addresses rather than unique facility codes. The text of the bill uses the term "place of business" to describe the required location disclosure. People familiar with negotiations stated that the Food and Drug Administration will have the final say in what counts as an acceptable address under the new rules.

Sens. Rick Scott and Kirsten Gillibrand introduced the Clear Labels Act earlier this year. The two senators issued a joint press release praising the bill’s progress as a "massive win for consumer safety and transparency." A representative from Gillibrand’s office stated the five-year delay allows time for FDA rulemaking and manufacturer compliance.

Retired Army Col. Vic Suarez said in an interview, ""It’s just a clear watering down of the original bill." Kevin Schulman, a professor of medicine and health policy at Stanford University, questioned the extended timeline. "Five years after it passes might as well be a lifetime," Schulman said."

Schulman also asked why industry stakeholders resist stricter identification measures. "Why is it that the supply chain, the medical distributors and the retailers don’t want to make sure that they supply the highest-quality product?." he said. Former FDA inspector Peter Baker expressed skepticism about the need for such a long implementation period. If they wanted to do it in one year, they could, Baker said.

Baker added that the regulatory burden does not justify the delay. I would love to hear their justification on why they need five years to develop some rules and guidance on transparency. … I mean, it’s a simple label change," he said. People familiar with the deliberations stated that lawmakers removed provisions due to concerns that they would raise drug prices and weaken national security."

Why It Matters

The amendments to the Clear Labels Act alter how consumers and regulators can identify where prescription drugs are manufactured. By replacing unique facility codes with the term "place of business," the legislation shifts the burden of interpretation to the FDA. Critics contend this change could allow manufacturers to list corporate headquarters or importer locations instead of actual production sites, maintaining the status quo of limited supply chain visibility.

The five-year compliance window extends the timeline significantly beyond the original one-year proposal. This delay provides manufacturers and the FDA ample time to adjust to the new labeling requirements, but it also postpones the implementation of transparency measures. The removal of DUNS numbers eliminates a specific, standardized identifier that was present on the majority of reviewed generic drug labels, raising questions about the precision of future location disclosures.